{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:22:52Z","timestamp":1781151772036,"version":"3.54.1"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004876","name":"Sheffield Hospitals Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004876","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Multiple myeloma is an incurable haematological cancer. The increase in targeted therapies has improved the number of myeloma patients achieving a complete response and improved progression-free survival following therapy. However, a low level of disease or minimal residual disease (MRD) still persists which contributes to the inevitable relapse in myeloma patients. MRD has been attributed to the presence of dormant myeloma cells and their subsequent reactivation, which is controlled by the microenvironment and specialised niches within the bone marrow. This contributes to the evasion of the immune system and chemotherapy, eventually leading to relapse. The growth of myeloma tumours are heavily dependent on environmental stimuli from the bone marrow microenvironment, and this plays a key role in myeloma progression. The bone microenvironment also plays a critical role in myeloma bone disease and the development of skeletal-related events. This review focuses on the bone marrow microenvironment in relation to myeloma pathogenesis and cancer dormancy. Moreover, it reviews the current therapies targeting the bone microenvironment to treat myeloma and myeloma bone disease. Lastly, it identifies novel therapeutic targets for myeloma treatment and the associated bone disease.<\/jats:p>","DOI":"10.3389\/fonc.2022.999939","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T06:22:39Z","timestamp":1661149359000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["The role of the bone microenvironment in regulating myeloma residual disease and treatment"],"prefix":"10.3389","volume":"12","author":[{"given":"Terry G.","family":"Dadzie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanna C.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9010003","article-title":"Epidemiology, staging, and management of multiple myeloma","volume":"9","author":"Padala","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"B3","article-title":"Seer cancer statistics review, 1975\u20132018","author":"Howlader","year":"2021","journal-title":"Natl Cancer Institute"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012854","article-title":"Requirements for operational cure in multiple myeloma","volume":"138","author":"Mohty","year":"2021","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13003","article-title":"A historical perspective on milestones in multiple myeloma research","volume":"100","author":"Ribatti","year":"2018","journal-title":"Eur J Haematology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000528","article-title":"Multiple myeloma: Eha-esmo clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: A pooled analysis of three Pethema\/Gem clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A Large meta-analysis establishes the role of mrd negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.801851","article-title":"Minimal residual disease assessment in multiple myeloma patients: Minimal disease with maximal implications","volume":"11","author":"Charalampous","year":"2022","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"14956","DOI":"10.1038\/s41598-021-94191-8","article-title":"Quantification of measurable residual disease in patients with multiple myeloma based on the imwg response criteria","volume":"11","author":"Narita","year":"2021","journal-title":"Sci Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40364-021-00328-2","article-title":"Minimal residual disease in multiple myeloma: Current status","volume":"9","author":"Ding","year":"2021","journal-title":"biomark Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.189159","article-title":"European Myeloma network recommendations on tools for the diagnosis and monitoring of multiple myeloma: What to use and when","volume":"103","author":"Jo","year":"2018","journal-title":"Haematologica"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective evaluation of magnetic resonance imaging and [(18)F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the Ifm\/Dfci 2009 trial: Results of the imajem study","volume":"35","author":"Moreau","year":"2017","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.160","article-title":"Navigating the bone marrow niche: Translational insights and cancer-driven dysfunction","volume":"12","author":"Reagan","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nature12984","article-title":"The bone marrow niche for haematopoietic stem cells","volume":"505","author":"Morrison","year":"2014","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","first-page":"8983","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","volume":"6","author":"Lawson","year":"2015","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood.2018880930","article-title":"A niche-dependent myeloid transcriptome signature defines dormant myeloma cells","volume":"134","author":"Khoo","year":"2019","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.44","article-title":"Bone metastasis: The importance of the neighbourhood","volume":"16","author":"Croucher","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/bjh.14807","article-title":"Cxcl12 and Cxcr7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma","volume":"179","author":"Waldschmidt","year":"2017","journal-title":"Br J Haematology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-186668","article-title":"Cxcr4 inhibitor Amd3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy","volume":"113","author":"Azab","year":"2009","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.5.1658","article-title":"Cell adhesion mediated drug resistance (Cam-dr): Role of integrins and resistance to apoptosis in human myeloma cell lines","volume":"93","author":"Damiano","year":"1999","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.576791","article-title":"Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microrna-15a expression","volume":"52","author":"Hao","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"B26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/B978-0-12-801238-3.11245-0","article-title":"Role of the osteoclast in cancer","volume-title":"Encyclopedia of bone biology","author":"Green","year":"2020"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14889","article-title":"Therapeutic targets in myeloma bone disease","volume":"178","author":"Marino","year":"2021","journal-title":"Br J Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-021-03767-0","article-title":"Morphogens and growth factor signalling in the myeloma bone-lining niche","volume":"78","author":"Morris","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.3390\/jcm10173973","article-title":"Myeloma bone disease: The osteoblast in the spotlight","volume":"10","author":"Andrews","year":"2021","journal-title":"J Clin Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(14)50017-5","article-title":"Microenvironment and multiple myeloma spread","volume":"133","author":"Ribatti","year":"2014","journal-title":"Thromb Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldu016","article-title":"Myeloma bone disease: Pathogenesis, current treatments and future targets","volume":"111","author":"Walker","year":"2014","journal-title":"Br Med Bull"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3793","article-title":"Mechanisms of disseminated cancer cell dormancy: An awakening field","volume":"14","author":"Sosa","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3858","article-title":"Inhibition of Eif2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy","volume":"69","author":"Schewe","year":"2009","journal-title":"Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-517136","article-title":"Osteoblastic niche supports the growth of quiescent multiple myeloma cells","volume":"123","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0222-x","article-title":"Trim44 promotes quiescent multiple myeloma cell occupancy and survival in the osteoblastic niche Via hif-1alpha stabilization","volume":"33","author":"Chen","year":"2019","journal-title":"Leukemia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3465","article-title":"Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments","volume":"19","author":"Fluegen","year":"2017","journal-title":"Nat Cell Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408419","article-title":"Pharmacologic stabilization of hif-1alpha increases hematopoietic stem cell quiescence in vivo and accelerates blood recovery after severe irradiation","volume":"121","author":"Forristal","year":"2013","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.stem.2010.06.020","article-title":"Regulation of the hif-1alpha level is essential for hematopoietic stem cells","volume":"7","author":"Takubo","year":"2010","journal-title":"Cell Stem Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0781-5","article-title":"Correction: Role of growth arrest-specific gene 6-mer axis in multiple myeloma","volume":"34","author":"Waizenegger","year":"2020","journal-title":"Leukemia"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06356.x","article-title":"Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappab ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma","volume":"135","author":"Terpos","year":"2006","journal-title":"Br J Haematology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404806","article-title":"Bortezomib inhibits human osteoclastogenesis","volume":"21","author":"von Metzler","year":"2007","journal-title":"Leukemia"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3889","article-title":"Targeting bortezomib to bone increases its bone anabolic activity and reduces systemic adverse effects in mice","volume":"35","author":"Wang","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06829.x","article-title":"Stimulation of new bone formation by the proteasome inhibitor, bortezomib: Implications for myeloma bone disease","volume":"139","author":"Oyajobi","year":"2007","journal-title":"Br J Haematology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-174300","article-title":"Bortezomib induces osteoblast differentiation Via wnt-independent activation of \u03b2-Catenin\/Tcf signaling","volume":"113","author":"Qiang","year":"2009","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3859","article-title":"Tgfbeta inhibition stimulates collagen maturation to enhance bone repair and fracture resistance in a murine myeloma model","volume":"34","author":"Green","year":"2019","journal-title":"J Bone Miner Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114100","article-title":"Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow","volume":"83","author":"Hughes","year":"1989","journal-title":"J Clin Invest"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003188.pub4","article-title":"Bisphosphonates in multiple myeloma: An updated network meta-analysis","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Systematic Rev"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(11)70157-7","article-title":"Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (Mrc myeloma ix): Secondary outcomes from a randomised controlled trial","volume":"12","author":"Morgan","year":"2011","journal-title":"Lancet Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: An international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (Excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: A Post hoc analysis of the randomized placebo-controlled freedom trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Mineral Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cell.2021.02.002","article-title":"Osteoclasts recycle Via osteomorphs during rankl-stimulated bone resorption","volume":"184","author":"McDonald","year":"2021","journal-title":"Cell"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-773341","article-title":"Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma","volume":"129","author":"McDonald","year":"2017","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.152","article-title":"Genetic deletion of sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth","volume":"31","author":"Delgado-Calle","year":"2017","journal-title":"Leukemia"},{"key":"B55","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.bone.2016.07.007","article-title":"Combined treatment with a transforming growth factor beta inhibitor (1d11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease","volume":"91","author":"Nyman","year":"2016","journal-title":"Bone"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3606","article-title":"Preventing and repairing myeloma bone disease by combining conventional antiresorptive treatment with a bone anabolic agent in murine models","volume":"34","author":"Paton-Hough","year":"2019","journal-title":"J Bone Miner Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-191577","article-title":"Anti-Dkk1 mab (Bhq880) as a potential therapeutic agent for multiple myeloma","volume":"114","author":"Fulciniti","year":"2009","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.081104","article-title":"Inhibiting dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma","volume":"24","author":"Heath","year":"2009","journal-title":"J Bone Miner Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2013.01.012","article-title":"In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma","volume":"53","author":"Pozzi","year":"2013","journal-title":"Bone"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12835","article-title":"Sotatercept in patients with osteolytic lesions of multiple myeloma","volume":"165","author":"Abdulkadyrov","year":"2014","journal-title":"Br J Haematology"},{"key":"B61","first-page":"786","article-title":"Abstract 786: Effects of combination treatment with cabozantinib and bortezomib inthe 5tgm1 murine multiple myeloma model.","author":"Suominen MI","year":"2015"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005865","article-title":"The characterization of distinct populations of murine skeletal cells that have different roles in b lymphopoiesis","volume":"138","author":"Green","year":"2021","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.999939\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T06:22:42Z","timestamp":1661149362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.999939\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":62,"alternative-id":["10.3389\/fonc.2022.999939"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.999939","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]},"article-number":"999939"}}